Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart BExp Clin Transplant 2005[Dec]; 3 (2): 381-4Posttransplant lymphoproliferative disorders are severe complications that arise after solid organ transplantation, which are often related to Epstein- Barr virus. Reports are anecdotal, and a standardized therapy does not exist. We report a case of a 36-year-old man who developed posttransplant lymphoproliferative disorder of the oropharynx 1 year after receiving a heart transplant. A short review of the literature is presented, after which a new therapeutic approach that combines antiviral therapy, monoclonal antibodies, and a sirolimus-based maintenance immunosuppression regimen with reduced target trough levels of tacrolimus is introduced. The patient achieved complete remission and was free from recurrence 18 months after the therapy was initiated.|Adult[MESH]|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Heart Transplantation/adverse effects[MESH]|Humans[MESH]|Immunologic Factors/*therapeutic use[MESH]|Immunosuppressive Agents/*adverse effects[MESH]|Lymphoproliferative Disorders/*drug therapy/etiology[MESH]|Male[MESH]|Oropharynx[MESH]|Rituximab[MESH] |